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Detection of terminal complement components in experimental
immune glomerular injury
STEPHEN ADLER, PATRICIA J. BAKER, PAMELA PRITZL, and WILLIAM G. COUSER
The Division of Nephrology, Department fMedicine, University of Washington, Seattle, Washington
Detection of terminal complement components in experimental immune
glomerular injury. Complement mediates giomerulonephritis by inflam-
matory cell-dependent and non-inflammatory cell-independent effects
on glomerular permeability. The latter may involve terminal compo-
nents of the complement system. We examined several models of
immunologic renal injury in the rat by immunofluorescence (IF) for
terminal complement components CS, C6, C7, and C8 in glomeruli
using antisera to human C5-8, which cross-react with the analogous rat
complement components. Rats with the heterologous and autologous
phases of passive Heymann nephritis (PHN) had proteinuria and I to
2+ capillary wall deposits of heterologous or rat IgG, rat C3, and C5-8.
Complement depletion with cobra venom factor (CVF) significantly
decreased proteinuria in both models and prevented deposition of all
complement components. Rats with active Heymann nephritis had
similar deposits of rat IgG and C5-8. Rats with anti-GBM nephritis and
aminonucleoside nephrosis had severe proteinuria which was not
affected by CVF treatment and deposits of CS-8 were absent. The
presence of terminal complement components in immune deposits in
experimental glomerular disease correlates with a functional role for
complement in mediating glomerular injury. These data support the
hypothesis that the terminal complement pathway may be a major
mediator of some types of immune glomerular injury.
Detection des constituants terminaux du complement au cours de
lesions immunes glomerulaires experimentales. Le complement est le
médiateur d'une glomérulonéphrite par des effets inflammatoires
cellule-dépendants, et non inflammatoires cellule-independants sur Ia
perméabilité glomerulaire. Ces derniers pourraient mettre en jeu les
constituants terminaux du système coniplémentaire. Nous avons
examine plusieurs modCles de lesions renales immunologiques chez le
rat par Ia immunofluorescence (IF) en cc qui concerne les constituants
complémentaires terminaux C5, C6, C7. et C8 dans les glomérules en
utilisant des antisérums contre C5-8 humain qui croisent avec les
constituants complémentaires analogues du rat. Des rats dans les
phases hétCrologue et autologue d'une nCphrite passive de Heymaun
(PHN) avaient une protéinurie et des dépdts sur les parois capillaires I
a 2 + d'IgG héterologue ou de rat. de C3 et de C5-8 de rat. Une depletion
complémentaire avec du facteur de venin de cobra (CVF) a diminué
significativement Ia protéinurie dans les deux modèles et a prévenu le
dépôt de tous les constituants complementaires. Des rats atteints d'une
nephrite active de Heymann avaient des dépôts identiques d'IgG et de
C5-8 de rat. Des rats atteints de nephrite anti-GBM Ct de nephrose aux
aminoglucosides avaient une protéinurie sévère non affectée par le
traitement au CVF et les depOts de C5-8 étaient absents. La presence
des constituants terminaux de complement dans les depOts immuns lors
des glomerulopathies experimentales est correlée avec un rOle fonction-
nel du complement dans Ia mediation des lesions glomerulaires. Ces
données sont en faveur de l'hypothèse que Ia voie terminale du
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complement peut étre un médiateur majeur de certains types de lesions
glomerulaires immunes.
The complement system is a well established mediator of
glomerular capillary wall injury induced by antibody deposition
in glomeruli [1—5]. Previous studies of nephrotoxic, or anti-
glomerular basement membrane (GBM) nephritis, by several
investigators [6—10] have established a correlation between
glomerular C3 deposition, neutrophil infiltration, and protein-
uria; they have shown that proteinuria can be markedly reduced
by depletion of either complement or neutrophils and estab-
lished that proteinuria can be restored in normocomplemen-
temic, neutrophil-depleted animals by neutrophil replacement.
Based on these findings, as well as the known chemotactic
capacity of complement activation products, such as C5a, for
neutrophils in vitro [11], and the capacity of neutrophil-derived
enzymes to digest GBM in vitro [12], it has long been assumed
that the major role for complement in the pathogenesis of
immune renal injury was an indirect one mediated through
inflammatory effector cells [6—8].
We have recently shown that proteinuria induced by the in
situ formation of immune complexes in the subepithelial space
due to antibody reacting with either fixed or planted glomerular
antigens is highly complement-dependent but occurs indepen-
dently of inflammatory cell participation, thereby demonstrat-
ing a direct effect of complement activation in the mediation of
proteinuria in experimental membranous nephropathy [4, 5].
We speculated that this direct effect may result from a terminal
complement mechanism, perhaps involving assembly of mem-
brane attack complexes (MACs), with consequent injury to
some component of the filtration barrier. Support for this
hypothesis has been provided by our recent studies in which C6
deficient rabbits in the early phase of cationic-bovine serum
albumin (BSA) induced chronic serum sickness and in the
heterologous phase of nephrotoxic nephritis have a marked
reduction in proteinuria compared to normo-complementemic
controls despite equivalent amounts of glomerular antibody
deposition [13, 141. Additional indirect support for this hypoth-
esis derives from several recent demonstrations of neoantigens
of the MAC in glomerular immune deposits and elsewhere in a
variety of human renal diseases [15—1 7] and in serum sickness in
thc rat [18]. However, in none of these studies were the lesions
examined known to be complement-mediated. Moreover, the
observation of MAC localization at sites of presumably non-
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immune tissue injury, such as areas of sclerosis, vascular
thickening, and interstitial disease, raised questions regarding
whether terminal complement components and MAC formation
represent a primary pathogenetic mechanism or a secondary
manifestation of tissue injury from a variety of other causes.
To further explore the correlation between deposition of
terminal complement components, glomerular injury mani-
fested by proteinuria, and the role of complement in mediating
tissue damage, we established the specificity of antibodies for
terminal rat complement components C5, C6, C7, and C8. We
then utilized these antibodies to study the deposition of terminal
complement components in a variety of immune and non-
immune glomerular lesions in the rat in which the participation
or non-participation of complement in mediating the lesions
could be established. Our findings demonstrate a close correla-
tion between glomerular deposition of terminal complement
components and complement-dependent glomerular injury and
support the hypothesis that a terminal complement mechanism
is an important primary mediator of immune glomerular disease.
Methods
Assay of rat complement components
Rat serum was assayed for C5, C6, C7, and C8 hemolytic
activity using purified complement components and cellular
intermediates obtained from Cordis Laboratories (Miami, Flor-
ida) using a modification of the manufacturer's method. The
hemolytic assay was carried out in GGVB + + buffer consisting
of equal volumes of 5% glucose and 0.04 M veronal buffered
saline, pH 7.3 with 0.1% gelatin, 0.25 msi Ca, and 0.5 mM
Mg EAClgp4hu, human C2, C3, CS, C6 and C7, and guinea
pig C8 and C9 were used to measure CS, C6, and C7 activity.
EAClgp4-7hu and human C9 were used to measure C8 activity.
Serial dilutions of rat serum were made in GGVB +buffer. The
reaction mixture consisted of 57 l aliquots of indicator cells,
serum dilutions, and all of the complement components except
the one being assayed with a final volume of 235 1d. Following
incubation at 37°C, 465 pA of saline were added and the
absorption of the supernatants at 415 nm determined
spectrophotometrically. The percentage of lysis was deter-
mined by comparison to an equal volume of cells lysed in
distilled water. From a linear regression plot of -In (l-% lysis)
versus serum dilution, the dilution giving 50% lysis was calcu-
lated. The reciprocal of this value is the number of CH5O units
per milliliter.
Antisera to rat complement components
Monospecific goat antisera to human CS, C6, and C7 were
obtained from Cappel Laboratories (Cochraneville, Pennsylva-
nia) and the fluorescein conjugated IgG fraction of goat anti-
serum to human C8 was obtained from Atlantic Antibodies
(Scarborough, Maine). All antisera were heat-inactivated prior
to use. Antisera were tested by micro-Ouchterlony immunodif-
fusion for reactivity against fresh normal human, sheep and rat
serum, and IgG. To further insure non-reactivity with deposits
of sheep or rat IgG present in glomeruli in the models studied,
sheep IgG was fixed to rat tissue sections by incubating
heat-inactivated (56°C, 30 mm) sheep anti-Fx1A antiserum with
cryostat sections of normal rat kidney for 30 mm at room
temperature to produce hrushborder deposits of sheep IgG [13].
Deposits of rat immunoglobulin G (IgG) were fixed to tissue
sections in a similar distribution by incubating some of the
sheep IgG containing sections with heat-inactivated rat anti-
sheep IgG antiserum. Such sections stain positively for both
sheep and rat IgG on tubular brush borders, but do not stain
with antiserum to goat IgG. Sections containing deposits of
sheep IgG alone or sheep and rat IgG without complement,
were then stained with the goat antisera to complement com-
ponents for 30 mm followed by staining with fluorescein-
conjugated sheep anti-goat IgG (Cappel Laboratories, Inc.).
Antisera to complement components and goat IgG were used at
the highest dilution which produced a precipitin line against
undiluted normal human or goat serum in micro-Ouchterlony
immunodiffusion. Controls included sections with positive
staining for complement components stained directly, or fol-
lowing incubation with heat-inactivated normal goat serum,
with fluorescein-conjugated sheep anti-goat IgG, and normal rat
kidneys stained with the antisera to human complement com-
ponents and sheep anti-goat IgG. Because purified rat comple-
ment components are not available, specific absorption studies
were not carried out.
Because antiserato human complement components did not
make precipitin lines against fresh rat serum in micro-
Ouchterlony immunodiffusion, further studies were carried out
to assess the capacity of each antiserum to specifically neutral-
ize the functional activity of the corresponding individual rat
complement component. For these studies, the IgG fraction of
antiserum to human C6, C7, and C8 was isolated by ion-
exchange chromatography on DEAE-Sephacel (Pharmacia Fine
Chemicals, Piscataway, New Jersey) in 0.0175 M sodium phos-
phate buffer, pH 7.4. IgG fractions of antiserum were concen-
trated to 2 mg/mI before use and were shown to lack comple-
ment component activity using the assay outlined above. To
determine the dilution of rat serum to be used in neutralization
studies, fresh normal rat serum was first assayed for CS, C6,
C7, and C8 hemolytic activity as described above. Dilutions of
rat serum which gave 90% hemolysis in the complement com-
ponent assay were then mixed with 1:2 or 1:4 dilutions of
antiserum or antibody IgG to the respective complement com-
ponents and incubated at 25°C for 30 mm. As controls, ad-
ditional aliquots of the same dilutions of normal rat serum were
incubated alone, or with equivalent concentrations of normal
goat serum or IgG. Following incubation, the rat sera were
assayed again for CS, C6, C7, and C8 hemolytic activity,
respectively.
Models of glomerular disease
Passive Heymann nephritis (PHN-heterologous phase).
PHN was induced in five male Sprague-Dawley rats (Tyler
Laboratories, Inc., Bellevue, Washington) by injection of 1.25
ml i.v. of sheep anti-FxlA antiserum prepared as previously
described [19, 201. Sheep were hyperimmunized with rat proxi-
mal tubular epithelial cell brushborder antigen (Fx1A) prepared
according to the method of Edgington, Glassock, and Dixon
[21]. Antisera were absorbed with rat red blood cells and
plasma and heat-inactivated (56°C, 30 mm) prior to use. Sheep
anti-rat FxIA was not reactive with rat serum by micro-
Ouchterlony immunodiffusion and immunoelectrophoresis
(IEP), but made two precipitin lines against a suspension of
crude rat FxlA (10 mg/mI) [211. An additional four rats were
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given the same dose of antiserum but were also depleted of
circulating complement by injection of purified cobra venom
factor (CVF, Cordis Laboratories) beginning the day prior to
antiserum injection and continuing for 5 days as described
below. Urine protein excretion was measured from days 4 to 5
following antiserum injection; tissue samples for im-
munofluorescence (IF) studies were obtained on day 5.
-y2-PHN(heterologous phase). To study animals with equiva-
lent quantities of subepithelial sheep IgG deposits but without
proteinuria or complement fixation, PHN was induced with the
y2 (non-complement fixing) IgG fraction of sheep anti-rat FxlA
[4]. The y2 fraction was isolated from a 50% ammonium sulfate
precipitate of whole antiserum by ion-exchange chromatogra-
phy on DEAE-Sephacel (Pharmacia Fine Chemicals) using
0.0175 M sodium phosphate buffer, pH 7.4 14, 51. The y2
fraction made a single line in micro-Ouchterlony immunodiffu-
sion and IEP against rabbit antiserum to whole sheep serum and
sheep IgG (Cappel Laboratories, Inc.). Three rats were injected
with 9.3 mg of y2 anti-Fx1A i.v. and studied 3 days later.
y2-PHN (autologous phase). To obtain a model of comple-
ment-dependent proteinuria induced by antibody reacting with
an exogenous, planted subepithelial antigen, we immunized
four rats with sheep IgG, 1.0 mg in complete Freund's adjuvant
(Difco Laboratories, Detroit, Michigan) to accelerate develop-
ment of the autologous phase, and then we injected the rats 5
days later with 8.1 mg i.v. of y2 anti-FxlA. This protocol
produces subepithelial deposits of planted sheep IgG antigen,
rat anti-sheep IgG antibody, and rat C3; proteinuria develops
approximately 7 days following injection of the y2 and anti-
Fx1A [5]. An additional three rats, treated as above, were
depleted of circulating complement using CVF as described
below. Urine protein excretion and tissue for IF studies was
obtained on days 7 to 8 following antibody injection.
Autologous immune complex nephropathy (AICN). AICN
was induced by immunizing five male Lewis rats, weighing 150
to 200 g, (Simonsen Laboratories Inc., Gilroy, California) in the
rear foot pads with 5 mg of FxIA emulsified in complete
Freund's adjuvant (Difco Laboratories) as described previously
[22]. Urine protein excretion and IF studies were carried out 7
weeks following immunization.
Nephrotoxic nephritis (heterologous phase). Six rats were
injected with 0.125 ml i.v. of sheep anti-rat GBM antiserum,
prepared as described previously [23, 24]. Sheep were hyperim-
munized with intact rat glomeruli prepared by differential
sieving techniques [24], and antiserum was absorbed and heat-
inactivated as described above for anti-Fx1A. Protein excretion
was measured during the 24-hr period following antiserum
injection, and tissue for IF study was obtained by open renal
biopsy 4 and 24 hr after antiserum injection. To assess the role
of complement in mediating proteinuria in this model, six
additional rats were treated with CVF as described below.
Urine protein excretion was measured during the 24-hr period
following antiserum injection and tissue for IF study was
obtained by open renal biopsy 24 hr following antiserum
injection.
y2 anti-rat GBM nephritis (heterologous phase). To study
another group of rats with equivalent amounts of anti-GBM
antibody deposition without complement fixation, the y2 (non-
complement fixing) fraction of sheep anti-rat GBM IgG was
isolated as described above for y2 anti-Fx1A, Three rats were
each injected with 10 mg i.v. of y2 anti-rat GBM IgG and
studied as described for the group with nephrotoxic nephritis
above.
Aminonucleoside nephrosis. To obtain a model of non-
immune glomerular disease, we induced proteinuria in three
rats by an intravenous injection of 100 mg/kg of
aminonucleoside of puromycin (PA; 1CM Pharmaceuticals,
Inc., Life Sciences Group, Cleveland, Ohio) in normal saline as
described previously [251. Proteinuria was measured and renal
tissue obtained for IF studies 9 days after PA injection.
Other procedures
Rats were depleted of circulating complement by injection of
CVF (Cordis Laboratories, Inc.), 300 U/kg i.p. in four divided
doses beginning the day prior to antibody injection and followed
by daily injections of 100 U/kg i.p. for the duration of the
experiment, following a protocol described by Cochrane, Muller-
Eberhard, and Aikin [3]. Our previous studies demonstrate that
this regimen reduces serum C3 levels to less than 10% of normal
[4, 5].
Urine protein excretion was measured on 24-hr urine collec-
tions obtained in metabolic cages. Protein content was mea-
sured by the sulfosalicylic acid method [26] using a commercial
standard (Lab-trol, Dade Diagnostics, Inc., Aguado, Puerto
Rico). Normal 24-hr urine protein excretion in age-matched rats
in our laboratory has been 2 to 6 mg.
Tissue samples for IF were obtained by open renal biopsy
while the rats were under ether anesthesia or at sacrifice and
snap-frozen in dry-ice-isopentane. Cryostat sections were cut at
4 , air-dried, and fixed in ether-alcohol as described elsewhere
[25, 27]. In addition to the goat antisera to complement com-
ponents and sheep anti-goat IgG described above, sections
were also stained with the fluorescein-conjugated fraction of
monospecific rabbit anti-sheep IgG and anti-rat C3 (Cappel
Laboratories, Inc.). Stained sections were examined on a Zeiss
photomicroscope III with an epifluorescence condenser and
appropriate filters for FITC fluorescence (Carl Zeiss, Inc.,
Thornwood, New York). Sections were photographed on Ko-
dak Ektachrome ED-135 film (Eastman Kodak Co., Rochester,
New York) using an automatic exposure meter set at ASA-400.
The intensity of fluorescent staining was reported
semi-quantitatively on a 0 to 4 + scale, with 0, indistinguishable
from control; trace, visible but cannot be photographed; 1 +,
definite but faint; 2+, definite; 3+, moderate intensity; and
4+, maximum intensity. Maximum intensity was taken to be
the staining observed in rats injected with nephrotoxic serum or
in AICN rats biopsied 7 weeks after immunization with FxIA.
Statistical analysis of data
All results of urine protein excretion determinations are
expressed as mean SEM. The Mann-Whitney test was used to
compare the results of protein excretion in different groups [28].
P values less than 0.05 are regarded as significant.
Results
Specificity of antisera and reactivity with rat complement
components
In micro-Ouchterlony, antiserum to human C5, C6, C7, and
C8 made single precipitin lines with fresh human serum. When
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Table 1. Neutralization of rat hemolytic complement activity by
antisera to human complement
Residual complement activity (CH5O U/mi) following incubation with:
GGVBa
Normal serum
or IgG
Antiserum
or Ab IgG
C5 823 420 <4b
C6 10,400 10,500 l,l00c
C7 36,200 48,600 2,523c
C8 346,000 412,000 54,700c
For the makeup of GGVB, a complement assay buffer, see
Methods.
b Whole antiserum to CS was used.
lgG fractions of antisera were used.
placed in adjacent wells, each antiserum made a line of non-
identity with the lines made by antisera to the other comple-
ment components, demonstrating the specificity of the indi-
vidual antibodies for the respective human complement com-
ponents. None of the antisera made precipitin lines in micro-
Ouchterlony or IEP against fresh rat serum. To test for the
reactivity of these antisera with rat complement components.
studies were carried out to assess the capacity of each anti-
serum to neutralize the functional activity of individual com-
plement components in rat serum. Results of a typical neutrali-
zation experiment are presented in Table I. Heat-inactivated
antiserum to human CS, and the IgO fraction of antiserum to
human C6, C7, and C8 had no significant residual hemolytic
activity when tested for CS. C6. C7, and C8. respectively.
When normal rat serum was incubated alone or with concentra-
tions of normal goat serum or goat IgG comparable to those in
the antibody preparations, no significant changes in levels of rat
CS, C6, C7, or C8 were observed (Table 1). However, incuba-
tion with whole antiserum or IgG fractions of antisera to
complement components under the conditions described re-
sulted in a loss of over 90% of the hemolytic activity of rat CS,
C6. and C7 and over 80% of the hemolytic activity of C8 (Table
1).
Studies to assess the possible cross-reactivity of these anti-
sera with other serum proteins which might be present in
glomerular deposits in the models studied, including sheep and
rat lgG, revealed no reactivity of any of the anti-complement
antisera with sheep or rat serum or lgG by micro-Ouchterlony.
The antisera also did not react by indirect IF with sheep or rat
lgG deposited on rat kidney sections. Similarly, the FITC-
conjugated sheep anti-goat IgO used to detect the binding of
antibody to complement components was not reactive with the
sheep or rat serum in micro-Ouchterlony and did not stain
sheep or rat lgG fixed to rat kidney sections. Deposit-containing
sections incubated with normal goat serum and FITC-
conjugated sheep anti-goat IgG demonstrated no non-specific
binding of goat lgG to the deposits.
I'rese/lce of teriiiinal rat (-o/nplenlent (OtflpO/?eflts 1/i
glomertilar disease modeLs
Passive Heymann nephrilis (heterologous phase). Five days
after receiving an injection of sheep anti-i-at FxlA antiserum.
the rats exhibited 2 to 3 + finely granular deposits of sheep IgO
and Ito 2+ deposits of rat C3 in a subepithelial distribution in
glorneruli as previously described [4, 20]. Faint deposits of lgG
and C3 were present focally on tubular brush borders. Oc-
casional deposits were also noted in a granular pattern along the
basement membranes of proximal convoluted tubules. Urine
protein excretion was 138 27 mg/day. Staining for CS, C6,
C7, and C8 revealed readily detectable (I to 2+) deposits of
each of the components in the glomerulus in a distribution
similar to that of IgG (Table 2, Fig. 1). Terminal complement
components were not detected along the tubule basement
membranes or proximal tubular brush borders. Rats depleted of
circulating complement components with CVF had similar
deposits of sheep IgG but no deposits of rat C3, CS, C6, C7. or
C8 (Fig. 2). Urine protein excretion in these animals was
reduced to 8.1 1.9 mg/day (P < 0.05 vs. controls; Table 2).
y2 PHJ'/ (heterologous phase). Three days following injection
of y2 sheep anti-FxIA lgG, I to 2+ glomerular capillary wall
deposits of sheep IgG were present in a distribution similar to
that described above. No rat IgG was present. Previous studies
demonstrate that urine protein excretion is normal in these
animals at this time [5]. IF staining for rat C3, CS, C6, C7. and
C8 was uniformly negative (Table 2).
y2 PHN (autologous phase). Rats were immunized with
sheep IgG prior to injection of y2 anti-FxIA IgG to accelerate
the development of the autologous phase. When these rats were
studied 8 days following the injection of antibody, sheep lgG
was still present in the glomerular capillary wall in a 1 to 2 +
granular pattern and rat IgG was present in a similar distribu-
tion. IF staining revealed I to 2+ deposits of rat C3, CS, C6.
C7. and C8 (Table 2). Urine protein excretion was 15.1 7.2
mg/day. Treatment of three rats with CVF, beginning the day
before antibody injection, did not alter deposits of sheep and rat
IgG but abolished deposits of rat C3, CS, C6, C7, and C8. Urine
protein excretion fell to 1.2 0.2 mg/day (Table 2).
AICN. Seven weeks following immunization with FxlA.
AICN rats had diffuse 3 to 4 + subepithelial deposits of rat IgG
and 1 to 2+ deposits of rat C3, as described previously [221.
There were focal I to 2 + deposits of rat IgG on tubular brush
borders, but tubular basement membrane staining was not
detected. All rats had positive staining in their glomeruli for rat
CS, C6. C7. and C8 in a distribution similar to that of rat IgG
and C3 and appearing identical to that described under PHN
above (Table 2). Urine protein excretion was 36.7 11.3
mg/day Because of the time period required to induce the
disease, the role of complement in mediating proteinuria has not
been studied hut is presumed to be similar to that described in
PHN [4. 29].
ATephrotoxic nephrio.s (heterologous phase). Four hours fol-
lowing injection of sheep anti-rat GBM antiserum. 3 to 4+
linear deposits of sheep lgG were present in all glomeruli. C3
was present in trace amounts in one animal but all others were
negative at 4 hr. After 24 hr, sheep IgG staining was unchanged
and trace-I + deposits of rat C3, but not of CS. Co. C7, or C8
were detected along the GBM (Fig. 3). Urine protein excretion
was 220 38 mg/day (Table 2). Treatment of rats with CVF
abolished deposition of C3 at 24 hr but did not alter urine
protein excretion (308 24 mg/day, P > 0.05 vs. controls).
y2 Nephrotoxic nep/iritis (heterologotis phase). Following
injection of rats withy2 anti-CBM IgG. the deposition of sheep
IgG was similar to that of animals receiving whole antiserum at
y2 PHN
Heterologous phase (3 days; N = 3)
Autologous phase (8 days; N = 4)
CVF-treated (8 days; N = 3)
AICN (7 weeks; N = 4)
Nephrotoxic nephritis (NTN)
Heterologous phase (4 hr; N = 6)
Heterologous phase (24 hr; N = 6)
CVF-treated (24 hr; N = 6)
y2 NTN
Heterologous phase (4 hr; N = 3)
Heterologous phase (24 hr; N = 3)
Aninonucleoside nephrosis (9 days; N = 3)
Fig. 1. Immunofluorescence of kidney tissue removed 5 days following
injection of 1.5 rn/of sheep anti-rat FxIA antiserum. Granular capillary
wall deposits of sheep lgG (A), rat C3 (B). C5 (C), C6 (D), C7 (E), and
C8 (F) are evident. (Original magnification, x 500)
4 and 24 hr, but no deposits of any complement components
could be demonstrated (Table 2). Rats receiving y2 nephrotoxic
IgG developed a mild, heterologous phase proteinuria (9.0
1.7 mg/day).
Aminonucleoside nephrosis. Nine days following injection of
aminonucleoside, rats had 268 7 mg/day of proteinuria. IF
studies revealed focal I + mesangial deposits of rat IgG similar
to normals, but no detectable glomerular deposition of any of
the complement components (Table 2). Our previous laboratory
studies demonstrate that treatment with CVF has no effect on
the development of proteinuria induced by aminonucleoside [41.
Discussion
Several models of immunologic renal disease, in which dif-
ferent roles for complement have been proposed, were exam-
ined to correlate the presence of deposits of terminal comple-
Fig. 2. Irnmunqfluorescence of kidney tissue removed 5 days following
injection of 1.5 ml of sheep anti-rat FxlA antiserum in cobra venom
factor-treated rats. Granular capillary well deposits of sheep IgG (A)
are present but no deposits of C3 (B), CS (C), C6 (D), C7 (E), or C8 (F)
are seen. (Original magnification, x 500)
ment components with the role of complement in causing
glomerular injury, to support the hypothesis that fixation of
terminal complement components in glomerular immune depos-
its may be a primary pathogenetic event. To do these studies, it
was first necessary to verify that antisera against the terminal
components of the human complement system reacted specifi-
cally with the same complement components in rat serum.
Following incubation of rat serum with antibody to the compo-
nent being evaluated, the hemolytic titer of that component in
normal rat serum was markedly depressed, whereas incubation
with assay buffer alone or normal goat serum or IgG led to no
significant change in titer. Furthermore, comparison of each
antiserum against all of the others in immunodiffusion versus
normal human serum demonstrated no reactivity of any of the
antisera with any of the components recognized by the other
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Table 2. Results of iF and protein excretiona
Passive Heymann Nephritis (PHN)
Heterologous phase (5 days; N = 5) + Tr(4/5)
CVF-treated (5 days; N 4) + +
24° Urine protein
Sheep IgG Rat IgG Rat C3 CS C6 C7 C8 excretion, mg
+
+
+
+
+
+
+
+
+
+
+
+ + + + + 138
— — — — 8.1± 1.9
— — - — — NT
+ + + + Tr 15.1±7.2
— — — — — 1.2± 0.2
+ + + + Tr 36.7±11.3
- - - - NT
+ — — — — 220
— — — — — 308
NT
— —
— — 9.0± 1.7
— — —
— — 268±7
Abbreviations and symbols: N, number tested; —, negative; +, present; Tr, trace; NT, not tested.
Values are means SEM.
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Fig. 3. Iminunofluorescence of' kidney tissue removed 24 hr following
injection of 0.15 ml of sheep anti-rat GBM antiserum, Linear deposits
of sheep IgG (A) are visible along the GBM. Faint deposit of rat C3 (B)
are visible, but CS (C), C6 (D), C7 (E), and C8 (F) are absent. (Original
magnification, x 500)
antisera. Failure to demonstrate reactivity between the antisera
and normal rat serum in micro-Ouchterlony immunodiffusion or
IEP may have been due to low avidity of the antibodies used or
to insufficient quantities of cross-reactive antigenic epitopes on
the complement components in normal rat serum to produce
visible precipitates.
Having demonstrated that these antisera react specifially
with, and neutralize, rat CS, C6, C7, and C8, the antisera were
then used in direct and indirect IF to examine renal tissue from
rats with different types of immunologic renal disease which
exhibit different roles for the complement system in the media-
tion of proteinuria. With respect to the membranous form of
glomerular injury, three models were studied. In the heterolo-
gous phase of PHN, subepithelial deposits form as a conse-
quence of antibody binding to an intrinsic glomerular antigen
[19, 29], and proteinuria is complement-dependent and cell-
independent [4]. In the present study, the complement-de-
pendence of this lesion induced with unfractionated IgG was
confirmed, and granular capillary wall deposits of C5, C6, C7,
and C8 were demonstrated in the same distribution as deposits
of rat C3 and sheep IgG in proteinuric animals. When rats were
treated with CVF to deplete complement during deposit forma-
tion, or when deposits were induced with the non-complement
fixing -y2 fraction of sheep JgG antibody, similar quantities of
IgG were deposited in the glomerulus but deposition of terminal
complement components was not seen and proteinuria did not
occur. These findings suggest that antibody deposition alone
does not result in non-specific localization of terminal compo-
nents in immune deposits and that the terminal complement
components may be involved in the pathogenesis of the func-
tional lesion which leads to proteinuria. Similar results were
observed in a second model of experimental membranous
nephropathy induced by using the 'y2 IgG as a planted sub-
epithelial antigen to induce in situ formation of epimembranous
immune complex deposits of sheep IgG and rat anti-sheep IgG.
Again, deposits of rat CS, C6, C7, and C8 corresponded to the
distribution of deposits of sheep IgG. rat IgG. and rat C3. CVF
treatment abolished both deposition of terminal complement
components and proteinuria. Finally, in the standard Heymann
nephritis (AICN) model induced by active immunization with
proximal tubule brushborder antigen, terminal complement
components were seen in proteinuric animals in a distribution
corresponding to that of rat IgO and C3. Although there is
evidence that immune deposit formation in AICN probably
occurs by an in situ mechanism similar to that demonstrated in
PHN [30, 311, the role of complement in mediating this lesion
has not been established because of the technical difficulties in
carrying out complement depletion studies for the 8-week
period required for proteinuria to develop in this model [22].
Because the antisera to C5-8 are directed against native
complement components, the presence of a MAC can only be
inferred. However, our data are consistent with our original
hypothesis that the mechanism of the direct effect of comple-
ment on glomerular permeability that we have now demon-
strated in several models of membranous nephropathy, prob-
ably involves participation of terminal complement components
to form a MAC with a resulting structural lesion occurring
somewhere in the distal portion of the filtration barrier [4, 32],
although some contribution of C3 cleavage products cannot be
ruled out. Further support for this hypothesis is provided by our
recent finding that C6 is required for the development of
proteinuria in the early phases of chronic serum sickness in
rabbits induced with cationized BSA when the glomerular
lesion is predominantly a membranous one [13], and by the
observations of others that neoantigens of the MAC are present
in glomerular immune deposits in both the idiopathic and lupus
forms of membranous nephropathy in humans [15, 16].
In addition to the cytolytic role of complement in immune
reactions, we have also shown that kidney cells damaged by a
variety of mechanisms and incubated in autologous serum have
the capacity to assemble a C3 cleaving enzyme on their sur-
faces, convert C3 by the classical and alternate pathways,
consume CS, C7, and C8 hemolytic activity and bind C5, C6,
C7, and C8 to their surfaces [331. To further exclude the
possibility that terminal complement component deposition
may be a secondary response to the tissue injury which resulted
in proteinuria, further studies were done in models of immune
and non-immune glomerular disease induced by complement-
independent mechanisms. Although others have described a
role for complement and neutrophils in the heterologous phase
of sheep anti-rabbit NTN [2, 3, 8], in our laboratory sheep
antibody to rat GBM induces heavy proteinuria without sig-
nificant C3 deposition or neutrophil infiltration, and comple-
ment depletion with CVF has no effect on proteinuria, a finding
that agrees with the results of Pilia et al [34]. In this model of
immunologically induced glonierular disease in which protein-
uria equals or exceeds that in the models of membranous
nephropathy, no terminal complement component deposition
was observed in normocomplementemic or complement-de-
pleted rats. Similar results were obtained in rats made
proteinuric by injection of the aminonucleoside of puromycin, a
lesion in which complement depletion has no effect on protein-
uria [4]. Although our findings do not exclude the possibility
that C5-9 assembly could be a secondary phenomenon due to in
situ processing of immune complex deposits by complement,
these findings suggest that deposition of terminal complement
components is probably not a consequence of glomerular injury
but rather a primary pathogenetic event. Taken together, these
results are again consistent with the hypothesis that a MAC-
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mediated form of injury may he an important aspect of comple-
ment participation in several forms of glomerular disease.
These results in animal models of immunologic glomerular
injury are consonant with observations in human renal disease.
Neoantigens of the MAC and poly-C9 have been found in
glomerular deposits of patients with systemic lupus
erythematosus, membranous nephropathy, anti-GBM disease
and a variety of other types of non-immunologic renal injury
[15—171. The mechanism by which direct or indirect MAC
damage to the glomerular capillary wall leads to increased
permeability is unknown. The MAC is able to insert into some
membranes and lipid bilayers to produce transmernbrane chan-
nels that lead to cell lysis 135, 361. It also appears to be able to
produce lytic lesions in bacterial cell walls and certain virus
particles [36]. An interaction with the cell membrane of the
glomerular epithelial cell or slit diaphragm has been postulated
but not demonstrated [4, 321. More recently, binding of C9 to
apparently cell-free alveolar basement membranes in the pres-
ence of antibody and normal serum has been demonstrated and
donut-shaped lesions in the membrane, believed to represent
the MAC inserted into the membrane, were also seen [371. The
mechanism by which terminal complement components partici-
pate in the alteration of glomerular permeability requires further
investigation.
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